第一代和第二代无心脏起器在患有鼻节律和完全心房阻塞的患者中的比较
Thibault Lenormand1, Kassem Abou Khalil1, Alexandre Bodin1
1Department of Cardiology, University Hospital of Tours, Tours, France.
Journal of cardiovascular electrophysiology
|June 24, 2023
概括
第二代无心脏起器 (AV) 在完全心脏起阻塞的患者中有效地提供心房同步,与第一代 (VR) 系统相比,显著降低了心脏起器综合征的风险.
科学领域:
- 心脏病学 心脏病学
- 生物医学工程 生物医学工程
- 医疗器械 医疗器械
背景情况:
- 无心脏起器 (LPM) 为传统节奏提供了替代品.
- 第一代Micra VR系统提供了VVI (R) 节奏,在鼻腔节律患者中风险起起因器综合征.
- 第二代Micra AV系统包含VDD节奏的心房机械传感器.
研究的目的:
- 为了比较第一代 (VR) 和第二代 (AV) Micra LPM 系统的有效性和安全性.
- 为了评估心房同步的实现和心脏起器综合征的发病率在鼻节律患者与完全心房阻塞.
主要方法:
- 植入LPM的患者的回顾性查,以检测完全心房静脉阻塞.
- 排除患有心房动,鼻功能障碍或低心室节奏负担的患者.
- 系统的随访,包括临床检查和心声回声.
主要成果:
- 包括93名患者:45名VR和48名AV. 基线特征相似,VR患者年龄较大.
- 该AV系统实现了78%心房同步心跳的中位数,其中65%>66%.
- 五名VR患者在一年内患上了心脏起器综合征,而AV组没有患者 (p=0.02).
结论:
- 在AV LPM中的心房机械传感算法能够实现显著的心房同步.
- 与VR系统相比,第二代AV系统与起器综合征的发病率降低有关.
- 腰部膜,特别是静脉膜系统,代表了为选定的患者提供安全有效的节奏解决方案.
相关概念视频
Dysrhythmias IV: Characteristics of Bradyarrhythmias
12
Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...
12
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.5K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.5K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
779
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
779
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.1K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.1K
Conduction System of the Heart
9.2K
Autorhythmicity is a term that refers to the heart's inherent ability to generate electrical signals and instigate muscle contractions. This self-regulating conduction system within the heart consists of two key components: the pacemaker cells and specialized conducting cells.
The pacemaker cells are located in two primary nodes: the sinoatrial (SA) node and the atrioventricular (AV) node. The SA node pacemaker cells can autonomously depolarize, triggering an action potential that leads to the...
The pacemaker cells are located in two primary nodes: the sinoatrial (SA) node and the atrioventricular (AV) node. The SA node pacemaker cells can autonomously depolarize, triggering an action potential that leads to the...
9.2K
Adrenergic Antagonists: ɑ and β-Receptor Blockers
524
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
524


